Abstract:Activity-based drug screens have successfully led to the development of various inhibitors of the catalytic activity of aurora kinases (AURKs), major regulatory kinases of cell division. Disrupting the localization of AURKB, rather than its catalytic activity, represents a largely unexplored alternative approach to disabling AURKB-dependent processes. Localization disruptors could be just as specific as direct inhibitors of AURKB activity, may bypass their off-target and select on-target toxicities, and are likely less susceptible to drug resistance resulting from mutations of the AURKB catalytic site. In this study, we demonstrate that the pan-AURK inhibitor AMG900 works at a low concentration not by inhibiting the phosphorylation of H3 at Ser10, an AURKB substrate, but by disrupting the mitotic localization of AURKB. Structural deletion studies pinpoint this undescribed activity to the 2-phenoxy-3,4′-bipyridine moiety of AMG900. Guided by a mechanism-informed phenotypic screening (MIPS) assay, the drug fragment is optimized into a novel class of inhibitors that, at low nanomolar concentrations, can disable AURKB through disruption of its mitotic localization and have desirable oral PK properties. Hierarchical clustering of cell fitness profiles reveals that these compounds cluster with each other, rather than with known AURK inhibitors such as AMG900 and VX-680. Validation studies in mice demonstrate that compound 15a elicits mitotic arrest and apoptosis in NCI–H23 human lung adenocarcinoma xenografts, resulting in a pronounced suppression of tumor growth. The discovery and optimization of compounds that disrupt AURKB localization are successfully facilitated by MIPS. Our findings suggest that 2-phenoxy-3, 4′-bipyridine derivatives have the potential to be further developed as effective therapeutics for the treatment of malignancy by delocalizing AURKB.

New Advances in Aurora Kinase and Its Anti-tumor Inhibitors

Development and Biological Evaluation of a Novel Aurora A Kinase Inhibitor

Targeting AURKA in Cancer: molecular mechanisms and opportunities for Cancer therapy

Identification of novel inhibitors of Aurora A with a 3-(pyrrolopyridin-2-yl)indazole scaffold.

Progress and Development in Research of Mitotic Kinases Inhibitors

A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics

The Role of Aurora-A in Human Cancers and Future Therapeutics.

Aurora A Kinase and Gynecological Tumors

Recent researches for dual Aurora target inhibitors in antitumor field

Emerging roles of Aurora-A kinase in cancer therapy resistance

Aurora A Is Essential for Early Embryonic Development and Tumor Suppression

Roles Of Aurora Kinases In Mitosis And Tumorigenesis

The significant others of aurora kinase a in cancer: combination is the key

Design and Synthesis of (E)-3-benzylideneindolin-2-one Derivatives As Potential Allosteric Inhibitors of Aurora A Kinase

Aurora-A Promotes the Establishment of Spindle Assembly Checkpoint by Priming the Haspin-Aurora-B Feedback Loop in Late G2 Phase

Discovery of Inhibitors of Aurora/PLK Targets As Anticancer Agents.

An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor

Recent progress in agents targeting polo-like kinases: Promising therapeutic strategies

Research progress on the relationship between AURKA and tumorigenesis: the neglected nuclear function of AURKA

2-Phenoxy-3, 4′-bipyridine derivatives inhibit AURKB-dependent mitotic processes by disrupting its localization

Orally Active Aurora A/B Kinase Inhibitor, AM‐005, Suppresses the Growth of Human Colon Carcinoma Cells